Levi & Korsinsky notifies investors that it has commenced an investigation into Mereo BioPharma Group plc (NASDAQ: MREO) concerning potential violations of the federal securities laws.
Mereo and its development partner Ultragenyx Pharmaceutical Inc. issued a press release on July 9, 2025, "announcing that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur "around the end of the year." Following this news, Mereo's American Depositary Receipt ("ADR") price fell over 42% on July 10, 2025.
If you suffered a loss on your Mereo BioPharma Group plc securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





